Why You Ought to Add Embody Well being to Your Portfolio Now

Embody Well being Company EHC is aided by rising affected person volumes, frequent growth initiatives and a powerful monetary place.

EHC’s Zacks Rank & Upbeat Value Efficiency

Embody Well being at the moment carries a Zacks Rank #2 (Purchase).

The inventory has gained 16.6% up to now 12 months in contrast with the business’s 7.2% development.

Picture Supply: Zacks Funding Analysis

EHC’s Favorable Model Rating

EHC carries a formidable Worth Rating of A. Worth Rating helps discover shares which can be undervalued. Again-tested outcomes have proven to date that shares with a positive Worth Rating together with a stable Zacks Rank are the very best funding bets.

Embody Well being’s Sturdy Progress Prospects

The Zacks Consensus Estimate for Embody Well being’s 2025 earnings is pegged at $5.30 per share, indicating a year-over-year enchancment of 19.6%. The consensus mark for revenues is pegged at $5.9 billion, implying a year-over-year improve of 10.4%.

The consensus estimate for 2026 earnings is pegged at $5.81 per share, indicating a rise of 9.6% from the 2025 estimate. The consensus estimate for revenues is pegged at $6.5 billion, implying 8.8% development from the 2025 estimate.

EHC’s Northbound Estimate Revision

The Zacks Consensus Estimate for 2025 earnings has been revised upward 0.2% up to now 60 days.

Embody Well being’s Spectacular Earnings Shock Historical past

EHC’s backside line outpaced estimates in every of the trailing 4 quarters, the typical shock being 12.47%.

EHC’s Key Enterprise Tailwinds

Embody Well being has exhibited stable income development, largely fueled by an increasing affected person base at its inpatient rehabilitation hospitals. For the primary 9 months of 2025, the corporate recorded an 10.6% improve in revenues in contrast with the identical interval within the prior 12 months. This robust efficiency is pushed by rising demand for specialised rehabilitative care that helps people recovering from continual diseases and accidents return to each day life. Such sustained demand is predicted to proceed supporting the momentum of the Inpatient Rehabilitation phase.

The corporate sees appreciable development potential on this phase, supported by a sequence of growth initiatives. Embody Well being ceaselessly launches new inpatient rehabilitation hospitals, both independently or in collaboration with outstanding healthcare companions, throughout varied U.S. communities. Every new facility enhances the corporate’s service capability and broadens its nationwide footprint.

As of now, Embody Well being operates 173 hospitals spanning 39 states and Puerto Rico. The most recent addition to its community was the Rehabilitation Hospital of Lake Price, which opened this December. 

In each 2026 and 2027, Embody Well being plans so as to add 150-200 beds to current services. The corporate’s means to execute its development technique is supported by a powerful monetary basis. As of Sept. 30, 2025, money and money equivalents totaled $48.7 million. Embody Well being generated $829.6 million in working money flows in the course of the first 9 months of 2025, representing an 14.6% improve 12 months over 12 months.

Different Shares to Think about

Another top-ranked shares within the Medical house are ANI Prescription drugs, Inc. ANIP, Collegium Pharmaceutical, Inc. COLL and Pediatrix Medical Group, Inc. MD, every at the moment sporting a Zacks Rank #1 (Sturdy Purchase). You possibly can see the whole record of right this moment’s Zacks #1 Rank shares right here.

ANI Prescription drugs’ earnings surpassed estimates in every of the final 4 quarters, the typical shock being 21.24%. The Zacks Consensus Estimate for ANIP’s 2025 earnings signifies an increase of 45.4% whereas the consensus mark for revenues implies an enchancment of 41.6% from the respective year-ago actuals. The consensus mark for ANIP’s 2025 earnings has moved 0.3% north up to now 30 days. 

Collegium Pharmaceutical’s earnings beat estimates in every of the trailing 4 quarters, the typical shock being 10.63%. The Zacks Consensus Estimate for COLL’s 2025 earnings signifies an increase of 17.1% whereas the consensus mark for revenues implies an enchancment of 24.2% from the respective year-ago actuals. The consensus mark for COLL’s 2025 earnings has moved 6.6% north up to now 60 days.

The underside line of Pediatrix Medical outpaced estimates in every of the trailing 4 quarters, the typical shock being 35.42%. The Zacks Consensus Estimate for MD’s 2025 earnings signifies an increase of 37.1% from the year-ago precise.  The consensus mark for MD’s 2025 earnings has moved 16.3% north up to now 60 days. 

Shares of ANI Prescription drugs, Collegium Pharmaceutical and Pediatrix Medical have gained 42.4%, 61.9% and 64.6%, respectively, up to now 12 months. 

Zacks Naming Prime 10 Shares for 2026

Wish to be tipped off early to our 10 prime picks for the whole thing of 2026? Historical past suggests their efficiency may very well be sensational.

From 2012 (when our Director of Analysis Sheraz Mian assumed duty for the portfolio) by means of November, 2025, the Zacks Prime 10 Shares gained +2,530.8%, greater than QUADRUPLING the S&P 500’s +570.3%.

Now Sheraz is combing by means of 4,400 firms to handpick the very best 10 tickers to purchase and maintain in 2026. Don’t miss your probability to get in on these shares after they’re launched on January 5. 

Be First to New Prime 10 Shares >>

Need the newest suggestions from Zacks Funding Analysis? Right now, you’ll be able to obtain 7 Greatest Shares for the Subsequent 30 Days. Click on to get this free report

Pediatrix Medical Group, Inc. (MD) : Free Inventory Evaluation Report

ANI Prescription drugs, Inc. (ANIP) : Free Inventory Evaluation Report

Collegium Pharmaceutical, Inc. (COLL) : Free Inventory Evaluation Report

Embody Well being Company (EHC) : Free Inventory Evaluation Report

This text initially printed on Zacks Funding Analysis (zacks.com).

Zacks Funding Analysis

The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.